[{"orgOrder":0,"company":"Theratechnologies","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Theratechnologies","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Theratechnologies"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"World Orphan Drug Alliance","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ World Orphan Drug Alliance","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ World Orphan Drug Alliance"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2022","type":"Financing","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Marathon Asset Management"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Theratechnologies","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Theratechnologies"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Windtree Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Windtree Therapeutics"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2021","type":"Agreement","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Piramal Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Piramal Pharma Solutions"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ PPD"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Theratechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Theratechnologies"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"PPD | Altasciences Company Inc | Windtree Therapeutics | Syneos Health | Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"TH1902","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ PPD | Altasciences Company Inc | Windtree Therapeutics | Syneos Health | Innovaderm","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ PPD | Altasciences Company Inc | Windtree Therapeutics | Syneos Health | Innovaderm"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TH1904","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Italian Medicines Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Italian Medicines Agency","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Italian Medicines Agency"}]
Find Clinical Drug Pipeline Developments & Deals by Theratechnologies
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
